Altimmune, Inc.
ALT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0% | 0% | 0% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -299,100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -369,840% | -437,040% | -404,520% | -462,920% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -380,280% | -442,920% | -391,500% | -463,600% |
| EPS Diluted | -0.21 | -0.27 | -0.26 | -0.33 |
| % Growth | 22.2% | -3.8% | 21.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |